Buy SAXENDA® 6mg/ml – 3 Syringes (Italian) Online

Saxenda® is a glucagon-like peptide-1 (GLP-1) receptor agonist used as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management. The active ingredient, liraglutide, is known for regulating appetite and reducing body weight by decreasing calorie intake. Saxenda® is indicated for patients with a BMI of 30 kg/m² or greater (obese) or a BMI of 27 kg/m² or greater (overweight) in the presence of weight-related comorbid conditions such as hypertension or type 2 diabetes mellitus.

Saxenda® Indications for Use

Saxenda® is prescribed for:

• Adult patients with a BMI of 30 kg/m² (obese) or greater.
• Adult patients with a BMI of 27 kg/m² or greater (overweight) who also have at least one weight-related comorbid condition.
• Pediatric patients aged 12 years and older, weighing more than 60 kg and having a BMI corresponding to 30 kg/m² for adults.

Limitations:

• Saxenda® should not be co-administered with other liraglutide-containing products or GLP-1 receptor agonists.
• The safety and efficacy of Saxenda® in pediatric patients with type 2 diabetes or in combination with other weight loss products have not been established.

Saxenda® Dosage Information

• Saxenda® is available as a 6 mg/mL solution in a 3 mL pre-filled syringe.
• The treatment starts at 0.6 mg daily for one week, increasing weekly to 1.2 mg, 1.8 mg, 2.4 mg, and finally reaching the maintenance dose of 3 mg daily.
• Administration: Subcutaneous injections should be administered in the abdomen, thigh, or upper arm. Saxenda® can be injected at any time of day, regardless of meals.

Dosage in Pediatric Patients:

• The recommended maintenance dose for pediatric patients is also 3 mg daily. However, if patients cannot tolerate this dose, it can be reduced to 2.4 mg.

Missed Doses:

• If more than 3 days have passed since the last dose, restart the dose at 0.6 mg and follow the escalation schedule to reduce gastrointestinal side effects.

Saxenda® Side Effects and Precautions

Common side effects reported in more than 5% of patients include:

• Nausea, diarrhea, constipation, vomiting.
• Injection site reactions, headache, dizziness, and fatigue.
• Hypoglycemia (especially in patients with type 2 diabetes).

Serious side effects include:

• Thyroid C-cell tumors: Animal studies showed the risk of medullary thyroid carcinoma (MTC); however, this is unconfirmed in humans. Patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use Saxenda®.
• Acute pancreatitis: Patients should discontinue use if pancreatitis is suspected.
• Acute gallbladder disease: Cholelithiasis and cholecystitis have been observed.
• Suicidal thoughts or behavior: Monitor patients for depression and suicidal ideation.

Contraindications:

• Hypersensitivity to liraglutide or any excipients in Saxenda®.
• Pregnancy: Saxenda® is contraindicated due to potential harm to the fetus.

Saxenda® Clinical Studies and Outcomes

Adult Clinical Trials:

• A 56-week trial involving 3291 patients showed that Saxenda® led to significant weight loss in adults, with 9.8% discontinuing due to adverse reactions such as nausea, vomiting, and diarrhea.
• Most common side effects: nausea (39.3%), diarrhea (20.9%), constipation (19.4%), and vomiting (15.7%).

Pediatric Clinical Trial:

• A 56-week study with 125 pediatric patients aged 12 to 17 showed similar outcomes. Nausea (42.4%) and vomiting (34.4%) were the most common side effects. One pediatric patient committed suicide, though a direct link to Saxenda® could not be confirmed.

Saxenda® Drug Interactions

• Saxenda® delays gastric emptying, potentially affecting the absorption of oral medications. Monitor for altered absorption of drugs taken concomitantly.
• There are no clinically significant interactions with common medications like oral contraceptives.

Saxenda® Administration Instructions

• Injections are to be administered subcutaneously in the abdomen, thigh, or upper arm.
• Patients should be trained on proper injection techniques, and injection sites should be rotated to avoid cutaneous amyloidosis (localized thickening of the skin).

Saxenda® Warnings and Precautions

• Thyroid C-Cell Tumors: Saxenda® may cause thyroid tumors in rats, and it is unclear if this applies to humans. Patients should be informed about the symptoms of thyroid tumors such as neck lumps or persistent hoarseness.
• Pancreatitis: Discontinue treatment if pancreatitis is suspected. It has been reported in 0.3% of adult patients in trials.
• Gallbladder disease: 2.2% of patients reported cholelithiasis, with 0.8% developing cholecystitis.
• Suicidal behavior: Monitor for changes in mood and mental health during treatment, and discontinue use if suicidal thoughts occur.